The Regulatory system of Canada, led by Health Canada, ensures drug safety, efficacy and quality through a framework of laws, policies and scientific review. B. Pharm students must understand drug approval pathways (New Drug Submission, Abbreviated NDS, Notice of Compliance), clinical trial applications, licensing, post-market surveillance, pharmacovigilance, Good Manufacturing Practices and the Drug Identification Number (DIN) system. Knowledge of the Food and Drugs Act, the Health Products and Food Branch, regulatory guidance documents, labelling requirements, import/export controls and controlled substances regulation prepares graduates for roles in pharmacy, industry or regulatory affairs. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. Which federal legislation is the primary legal framework governing drugs and pharmaceuticals in Canada?
- Controlled Drugs and Substances Act
- Food and Drugs Act
- Canada Health Act
- Pharmaceutical Regulatory Act
Correct Answer: Food and Drugs Act
Q2. Which branch of Health Canada is mainly responsible for regulating therapeutic products and ensuring their safety and efficacy?
- Biologics and Genetic Therapies Directorate
- Health Products and Food Branch
- Public Health Agency of Canada
- Canadian Food Inspection Agency
Correct Answer: Health Products and Food Branch
Q3. What does NDS stand for in the Canadian drug approval process?
- New Drug Submission
- National Drug Safety
- Notice of Drug Science
- Nonclinical Drug Study
Correct Answer: New Drug Submission
Q4. Which number uniquely identifies an approved drug product for sale in Canada?
- DIN (Drug Identification Number)
- UPC (Universal Product Code)
- NOC (Notice of Compliance)
- MAA (Market Authorization Authorization)
Correct Answer: DIN (Drug Identification Number)
Q5. What document indicates that a drug has met regulatory requirements and can be marketed in Canada?
- Clinical Trial Application
- Notice of Compliance (NOC)
- Investigational New Drug (IND)
- Pre-Submission Letter
Correct Answer: Notice of Compliance (NOC)
Q6. A drug sponsor planning a clinical trial in Canada must submit which application to Health Canada?
- Clinical Trial Application (CTA)
- Post-Market Report (PMR)
- New Drug Submission (NDS)
- Importation Request
Correct Answer: Clinical Trial Application (CTA)
Q7. Which of the following best describes the role of Good Manufacturing Practices (GMP) in the Canadian regulatory system?
- Guidelines for clinical trial design
- Standards to ensure consistent manufacture and quality of drug products
- Policies for promoting generic substitution
- Rules for advertising prescription drugs
Correct Answer: Standards to ensure consistent manufacture and quality of drug products
Q8. Which regulatory submission is typically used for approval of a generic drug in Canada?
- New Drug Submission (NDS)
- Abbreviated New Drug Submission (ANDS)
- Special Access Submission
- Biologic License Application
Correct Answer: Abbreviated New Drug Submission (ANDS)
Q9. Which Health Canada program collects and analyzes adverse reaction reports to monitor post-market safety?
- Clinical Trials Registry
- MedEffect Canada (adverse reaction monitoring)
- Drug Pricing Board
- Pharmacy Inspection Program
Correct Answer: MedEffect Canada (adverse reaction monitoring)
Q10. What is the primary purpose of a Notice of Compliance with Conditions (NOC/c)?
- To authorize clinical trials with no oversight
- To allow conditional market access based on promising evidence while additional data are required
- To revoke a drug’s market authorization
- To register a natural health product
Correct Answer: To allow conditional market access based on promising evidence while additional data are required
Q11. Which regulatory requirement focuses on protecting participants’ rights and safety in Canadian clinical trials?
- Good Manufacturing Practices (GMP)
- Good Clinical Practice (GCP)
- Drug Identification Number (DIN)
- Bioequivalence Guidelines
Correct Answer: Good Clinical Practice (GCP)
Q12. What information is typically included in a New Drug Submission (NDS)?
- Marketing plan and pricing strategy only
- Comprehensive quality, nonclinical and clinical data on safety and efficacy
- Only bioequivalence data
- Patient names and prescription histories
Correct Answer: Comprehensive quality, nonclinical and clinical data on safety and efficacy
Q13. Which agency enforces controlled substance scheduling and criminal penalties, complementing Health Canada’s regulatory role?
- Public Health Agency of Canada
- Canada Border Services Agency
- Department of Justice under the Controlled Drugs and Substances Act
- Canadian Food Inspection Agency
Correct Answer: Department of Justice under the Controlled Drugs and Substances Act
Q14. For a biologic product, which aspect of regulation often requires specialized review compared with small-molecule drugs?
- Label design only
- Manufacturing complexity, immunogenicity and lot-to-lot variability
- Colour of packaging
- Consumer advertising permissions
Correct Answer: Manufacturing complexity, immunogenicity and lot-to-lot variability
Q15. What is the role of Health Canada’s inspectors in the pharmaceutical regulatory system?
- To approve clinical trial protocols
- To conduct GMP inspections and enforce compliance with regulations
- To set retail drug prices
- To issue patents for drugs
Correct Answer: To conduct GMP inspections and enforce compliance with regulations
Q16. Which document must a sponsor provide to demonstrate that a generic product is equivalent to a reference brand drug?
- Patient Information Leaflet
- Bioequivalence study report
- Manufacturing batch record only
- Clinical Trial Application
Correct Answer: Bioequivalence study report
Q17. What does the Drug Identification Number (DIN) on a label signify to pharmacists and consumers?
- It guarantees the product is the most affordable option
- It confirms the product has been evaluated and authorized for sale in Canada
- It indicates the product is natural and unregulated
- It shows the country of origin only
Correct Answer: It confirms the product has been evaluated and authorized for sale in Canada
Q18. Which is a key requirement of post-market surveillance by sponsors after a drug is authorized?
- No further obligations after approval
- Ongoing safety monitoring and reporting of adverse reactions
- Only annual financial reporting to Health Canada
- Mandatory free distribution to hospitals
Correct Answer: Ongoing safety monitoring and reporting of adverse reactions
Q19. Which Health Canada guidance would a manufacturer consult to prepare for a GMP inspection?
- Clinical Trial Application Guide
- Good Manufacturing Practices guidance and inspection checklists
- Pharmacy Practice Standards
- Advertising Standards for OTCs
Correct Answer: Good Manufacturing Practices guidance and inspection checklists
Q20. What is an important difference between a New Drug Submission (NDS) and a Supplemental NDS (SNDS)?
- NDS is for devices; SNDS is for drugs
- NDS is for initial market authorization; SNDS is for major changes to an already authorized product
- SNDS requires no data; NDS requires no data
- They are identical in purpose and content
Correct Answer: NDS is for initial market authorization; SNDS is for major changes to an already authorized product
Q21. Which pathway allows access to non-marketed drugs for patients with serious or life-threatening conditions in Canada?
- Notice of Compliance pathway
- Special Access Programme (SAP)
- Abbreviated New Drug Submission
- Food Establishment License
Correct Answer: Special Access Programme (SAP)
Q22. Who is primarily responsible for submitting adverse reaction reports to Health Canada?
- Manufacturers and healthcare professionals (and patients encouraged to report)
- Only the pharmacist who dispensed the product
- Only the patient
- Provincial ministers of health exclusively
Correct Answer: Manufacturers and healthcare professionals (and patients encouraged to report)
Q23. Which element is essential in an application establishing the quality of a pharmaceutical product?
- Clinical trial protocol only
- Detailed chemistry, manufacturing and controls (CMC) data
- Marketing slogans and branding
- Pharmacy store layout
Correct Answer: Detailed chemistry, manufacturing and controls (CMC) data
Q24. Health Canada’s therapeutic product reviews evaluate which core aspects before approval?
- Efficacy, safety and quality
- Only economic impact
- Advertising reach and social media presence
- Colour and shape of the pill
Correct Answer: Efficacy, safety and quality
Q25. Which Canadian regulatory mechanism addresses recalls and field safety corrective actions for marketed drugs?
- Drug pricing review
- Recalls and safety notices coordinated by Health Canada and manufacturers
- Patent prosecution
- Clinical Trial Application withdrawal
Correct Answer: Recalls and safety notices coordinated by Health Canada and manufacturers
Q26. Which type of review may Health Canada grant to expedite drugs that address serious conditions with unmet needs?
- Standard review with no priority
- Priority review
- Advertising expedited review
- Generics-only review
Correct Answer: Priority review
Q27. Which document outlines labelling requirements and patient information obligations for prescription drugs in Canada?
- Food and Drugs Act and related regulations and guidance on labelling
- International Trade Agreement
- Pharmacy interior design codes
- Patent law manuals
Correct Answer: Food and Drugs Act and related regulations and guidance on labelling
Q28. What role do Health Canada guidance documents serve for sponsors and manufacturers?
- They are legally binding statutes
- They provide scientific and procedural recommendations to support compliance and submissions
- They replace the Food and Drugs Act
- They detail provincial reimbursement policies
Correct Answer: They provide scientific and procedural recommendations to support compliance and submissions
Q29. In Canada, who grants licences to pharmacies and oversees dispensing practices?
- Health Canada directly licenses every pharmacy
- Provincial and territorial regulatory authorities (colleges of pharmacy)
- Canada Revenue Agency
- World Health Organization
Correct Answer: Provincial and territorial regulatory authorities (colleges of pharmacy)
Q30. Which practice improves regulatory compliance and quality culture within pharmaceutical companies in Canada?
- Ignoring inspection findings
- Implementing robust quality systems, training and continuous improvement
- Only focusing on marketing activities
- Outsourcing all responsibilities without oversight
Correct Answer: Implementing robust quality systems, training and continuous improvement
